Get the Stockscreener App
38.34
6.10%
-2.49
After Hours:
38.45
0.11
+0.29%
Corcept Therapeutics Inc stock is traded at $38.34, with a volume of 1.37M.
It is down -6.10% in the last 24 hours and up +2.62% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$40.83
Open:
$40.85
24h Volume:
1.37M
Relative Volume:
0.78
Market Cap:
$4.03B
Revenue:
$741.17M
Net Income/Loss:
$104.65M
P/E Ratio:
43.81
EPS:
0.8752
Net Cash Flow:
$162.57M
1W Performance:
-0.05%
1M Performance:
+2.62%
6M Performance:
-47.90%
1Y Performance:
-45.35%
1-Day Range:
$38.00
$40.85
1-Week Range:
$38.00
$41.92
52-Week Range:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
38.34 | 4.29B | 741.17M | 104.65M | 162.57M | 0.8752 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) - GlobeNewswire
Options Exercise: Hazel Hunt At Corcept Therapeutics Realizes $5.53M - Benzinga
CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations - NewMediaWire
CORCEPT THERAPEUTICS INVESTIGATION ALERT: Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
Corcept Therapeutics Faces Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is ... - Bluefield Daily Telegraph
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewswire Inc.
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm - PR Newswire
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
CORT shares plummet on FDA’s drug rejection letter reveal — here’s what retail has to say - MSN
CORT SECURITIES INVESTIGATION: Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - The Globe and Mail
Kaplan Fox is Investigating Possible Securities Violations Against Corcept Therapeutics, Inc. (CORT) - FinancialContent
CORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - NewMediaWire
FinancialContentCORCEPT THERAPEUTICS Is Being Investigated for Potential Securities Law ViolationsContact Kaplan Fox & Kilsheimer LLP - FinancialContent
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus
CORCEPT THERAPEUTICS SECURITIES INVESTIGATION: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law Violations - The Globe and Mail
Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then - Yahoo Finance
CORT Investors Have Opportunity to Join Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of "Hold" by Brokerages - MarketBeat
CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible FraudContact Levi & Korsinsky Today - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Published on: 2026-02-04 10:56:05 - baoquankhu1.vn
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - marketscreener.com
Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated – CORT - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutanix, Inc. - GlobeNewswire Inc.
Brown Capital Management LLC Makes New $19.95 Million Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT FRAUD INVESTIGATION: Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to Potential Securities Violations - NewMediaWire
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings - BioSpace
DJS Law Group Investigates Corcept Securities Violations - intellectia.ai
Rosen Law Firm Investigates Securities Claims for Corcept Shareholders - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares F - The National Law Review
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations - NewMediaWire
Corcept Therapeutics Faces FDA Warning Over Drug Efficacy Claims - intellectia.ai
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing - The AI Journal
Corcept Therapeutics (CORT) Shares Drop After FDA Feedback - GuruFocus
Berman Tabacco Announces Investigation of Corcept - GlobeNewswire
Corcept submitted lead asset for approval despite FDA flagging risk of 'significant review issues' - Fierce Biotech
CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say - Stocktwits
CORT Sees Increased Call Options Activity - GuruFocus
Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation – CORT - Business Wire
Commit To Purchase Corcept Therapeutics At $25, Earn 18.7% Annualized Using Options - Nasdaq
Corcept shares tumble after FDA letter reveals warnings before drug rejection - Yahoo! Finance Canada
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses - GlobeNewswire
Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug A - GuruFocus
Corcept stock down as FDA revises CRL (CORT:NASDAQ) - Seeking Alpha
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guyer William | Chief Development Officer |
Feb 03 '26 |
Option Exercise |
21.65 |
20,000 |
433,000 |
21,235 |
| Guyer William | Chief Development Officer |
Feb 03 '26 |
Sale |
40.87 |
20,000 |
817,334 |
1,235 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):